|Bid||32.50 x 51100|
|Ask||33.10 x 25600|
|Day's range||32.62 - 32.95|
|52-week range||27.37 - 37.07|
|Beta (5Y monthly)||0.46|
|PE ratio (TTM)||40.83|
|Forward dividend & yield||0.27 (0.83%)|
|Ex-dividend date||09 Nov 2022|
|1y target est||36.06|
A look at the shareholders of ResMed Inc. ( NYSE:RMD ) can tell us which group is most powerful. We can see that...
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...
- Acquisition expands ResMed’s SaaS business to Germany, first non-U.S. market - Outpatient therapy services added to ResMed’s growing SaaS offering portfolio - Purchase price of €958.6 million (US$997.5 million); deal will be accretive to non-GAAP diluted earnings per share SAN DIEGO and HILDESHEIM, Germany, Nov. 22, 2022 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced it has completed its €958.6 million acquisition of MEDIFOX DAN, a German leader in software solutions for a wi